Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus.
Exenatide is the first-in-class incretin mimetic for the treatment of type 2 diabetes. To assess exenatide's mechanism of action, therapeutic and adverse effects. Pharmacokinetics and pharmacodynamics of exenatide were reviewed, as well Phase I, II and III clinical trials, and postmarket reports. Exenatide improves fasting plasma glucose and HbA1c in type 2 diabetic patients not controlled on other antidiabetic drugs, due to its effects on glucose-dependent stimulation on insulin secretion, suppression elevated glucagon secretion, slowing the accelerated rate of gastric emptying, reduction of food intake and possible beta-cell preservation. Nausea and vomiting were the most common and dose-related side effects. Rare reports of acute pancreatitis do not appear greater than the rate in the general population of patients with type 2 diabetes.